On Monday, Shares of Apple Inc. (NASDAQ:AAPL), lost -0.48% to $111.58. 30.47 million shares of the company were exchanged.
Apple® declared that improved editions of all seven books in J.K. Rowling’s Harry Potter series are now accessible exclusively on the iBooks Store℠ for readers around the world to enjoy on their iPhone®, iPad®, iPod touch® and Mac®. Customers can download individual books featuring full original text, interactive animations and elaborate artwork bringing these beloved stories to life in a unique way. Harry Potter fans will also find annotations throughout their literary journey, written by the author herself.
Until now, the Harry Potter digital books have only been accessible for readers to purchase through the Pottermore Shop. Starting recently, iBooks® users can experience the books with all new exclusive custom covers for each title, and typography counting the custom Harry Potter typefaces and new section headers and drop caps.
The iBooks Store is accessible in 52 countries and offers dozens of categories counting cookbooks, history books, biographies, picture books and children’s books, with free books accessible in 155 countries.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of United States Steel Corporation (NYSE:X), declined -5.41% to $11.71, during its last trading session.
United States Steel Corporation (NYSE:X) declared that the Ontario Superior Court of Justice has approved a mutually agreed upon transition plan with U. S. Steel Canada (USSC) as part of USSC’s restructuring under Canada’s Companies’ Creditors Arrangement Act (CCAA) process. The agreement is an important step in separating the two parties.
Highlights of this agreement comprise:
- S. Steel will not be generating any sales on behalf of USSC;
- Going forward U. S. Steel will load its production on its U.S.-based mills;
- S. Steel shall transition away from providing any technical and engineering services associated with product development or sales with USSC, and U. S. Steel will not support any field quality claims made against USSC;
- S. Steel will continue to provide all shared services that USSC relies upon for up to 24 months, with the exception of sales;
- Should USSC enter into a new sale and restructuring process (SARP) in the future, U. S. Steel will not be a bidder.
United States Steel Corporation produces and sells flat-rolled and tubular steel products in North America and Europe. It operates through three segments: Flat-Rolled Products (Flat-Rolled), U. S. Steel Europe (USSE), and Tubular Products (Tubular).
At the end of Monday’s trade, Shares of Bristol-Myers Squibb Co (NYSE:BMY), inclined 2.03% to $62.70.
Bristol-Myers Squibb Company (BMY) declared that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR mutation or ALK translocation should have disease progression on appropriate targeted therapy proceeding to receiving Opdivo. In a Phase 3 trial, CheckMate -057, Opdivo demonstrated superior overall survival (OS) in formerly treated metastatic non-squamous NSCLC contrast to chemotherapy, with a 27% reduction in the risk of death (hazard ratio: 0.73 [95% CI: 0.60, 0.89; p=0.0015]), based on a prespecified interim analysis.1 The median OS was 12.2 months in the Opdivo arm (95% CI: 9.7, 15.0) and 9.4 months in the docetaxel arm (95% CI: 8.0, 10.7).1 This approval expands Opdivo’s indication for formerly treated metastatic squamous NSCLC to comprise the non-squamous patient population. Squamous and non-squamous NSCLC together represent about 85% to 90% of lung cancer cases.
This approval is the third for Opdivo in the United States this year, and is based on the results of the CheckMate -057 trial, a Phase 3 trial which demonstrated superior OS benefit for Opdivo vs. docetaxel in formerly treated metastatic NSCLC. Opdivo is the only PD-1 therapy to have been studied in a Phase 3 trial of patients with formerly treated squamous NSCLC and a separate Phase 3 trial of patients with formerly treated non-squamous NSCLC. Biomarker testing is not required for Opdivo.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
